백내장 수술 후 0.1% 히알우론산과 0.05% 사이클로스포린 A가 눈물막에 미치는 효과
Effect of 0.1% Sodium Hyaluronate and 0.05% Cyclosporine on Tear Film Parameters after Cataract Surgery
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
목적: 백내장 수술 후 히알루론산나트륨과 사이클로스포린 점안액이 눈물막에 미치는 영향에 대하여 알아보고자 하였다. 대상과 방법: 백내장 수술을 시행 받은 86명 109안을 대상으로 건성안이 없는 1, 2군(57명, 74안)과 건성안이 있는 3, 4군(29명, 35안)으로 나누어, 히알루론산나트륨만 사용한 1군(29명, 37안), 3군(14명, 17안), 히알루론산나트륨과 사이클로스포린 점안액을 사용한 2군(28명, 37안), 4군(15명, 18안)으로 나누어 사용 전과 사용 후 1주, 1, 2, 3, 6개월에 눈물막파괴시간, 기본눈물분비, 눈물청소율과 각막상피병증을 측정하였다. 결과: 눈물막파괴시간, 기본눈물분비와 눈물청소율은 1군에서 3개월, 2군에서 2개월, 3군에서 3개월, 4군에서 1개월, 각막상피병증은1, 2군에서 1개월, 3군에서 2개월, 4군에서 1개월째 수술 전 수치로 회복되었다. 결론: 히알루론산나트륨과 사이클로스포린의 병합 사용은 눈물막의 빠른 회복을 보이며, 특히 수술 전 건성안을 동반한 경우에 효과적이라 생각한다.
Abstract
Purpose: To evaluate the efficacy of topical 0.1% sodium hyaluronate (HA) and 0.05% cyclosporine A (CsA) on tear film parameters after cataract surgery. Methods: A total of 109 eyes of 86 patients who underwent cataract surgery were divided into four groups: 74 eyes without dry eye syndrome (groups 1 and 2) and 35 eyes with dry eye syndrome (groups 3 and 4). Groups 1 (37 eyes) and 3 (17eyes) used 0.1% HA only, while Groups 2 (37 eyes) and 4 (18 eyes) used both 0.1% HA and 0.05% CsA. Tear film break-up time (BUT), Schirmer’s test, tear clearance rate (TCR) and keratoepitheliopathy were evaluated before surgery and 1 week, 1 month, 2, 3 and 6 months after surgery. Results: BUT, Schirmer’s test and TCR recovered at postoperative 3 months in groups 1 and 3, after 2 months in group 2and after 1 month in group 4. Keratoepitheliopathy recovered at postoperative 1 month in groups 1, 2 and 4, after 2 months in group 3. Conclusions: The combined use of topical 0.1% HA with 0.05% CsA is helpful in restoring tear film parameters after cataract surgery especially in patients with dry eye syndrome.
참고문헌 (27)
- "The definition of classification of dry eye diseases", the Definition and Classification Subcommittee of the International Dry Eye WorkShop, pp.75~92 (2007), Ocul Surf
- Horwath-Winter J, "Early changes in corneal sensation, ocular surface integrity, and tear-film function after laser assisted subepithelial keratectomy", J Cataract Refract Surg, 30, pp.2316~2321 (2004)
- Li XM, "Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery", Cornea, 26, pp.16~20 (2007)
- Pflugfelder SC, "The diagnosis and management of dry eye a twenty-five-year review", Cornea, 19, pp.644~649 (2000)
- Nussenblatt RB, "Cyclosporine immunology, pharmacology and therapeutic us", Surv Ophthalmol, 31, pp.159~169 (1986)
- Hemady R, "Immunosuppressive drugs in immune and inflammatory ocular disease", Surv Ophthalmol, 35, pp.369~385 (1991)
- Jabs DA, "The eye in bone marrow transplantation", Arch Ophthalmol, 107, pp.1343~1348 (1989)
- Bhan AK, "T-cell subsets and Langerhans cells in normal and diseased conjunctiva", Am J Ophthalmol, 94, pp.205~212 (1982)
- Gilbard JP, "Effect of punctal occlusion by Freeman silicone plug insertion on tear osmolarity in dry eye disorders", CLAO J, 15, pp.216~218 (1989)
- 이은하, "건성안에서 실리콘 누점마개 삽입술이 눈물 오스몰과 단백질 성분에 미치는 영향", 대한안과학회지, 42(11), pp.1509~1514 (2001), 대한안과학회
- Yen MT, "The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects", Am J Ophthalmol, 131, pp.314~323 (2001)
- Pflugfelder SC, "Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor beta2 production", Cornea, 27, pp.64~69 (2008)
- Wilson SE, "Long term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment", Ophthalmology, 114, pp.76~79 (2007)
- Roberts CW, "Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye", Cornea, 26, pp.805~809 (2007)
- Raphael M, "Conjunctival biopsy in Sjögrens syndrome correlations between histological and immunohistochemical features", Histopathology, 13, pp.191~202 (1988)
- Kunert KS, "Analysis of topical cyclosporine treatment of patients with dry eye syndrome effect on conjunctival lymphocytes", Arch Ophthalmol, 118, pp.1489~1496 (2000)
- O'Brien PD, "Dry eye diagnosis and current treatment strategies", 4, pp.314~319 (2004)
- Small DS, "Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease", J Ocul Pharmacol Ther, 18, pp.411~418 (2002)
- Laibovitz RA, "Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitissicca", Cornea, 12, pp.315~323 (1993)
- Turner K, "Interleukin 6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion", Cornea, 19, pp.492~496 (2000)
- Stevenson D, "Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate to severe dry eye disease: a dose ranging, randomized trial", Ophthalmology, 107, pp.967~974 (2000)
- Jun Woong Moon, "Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye", Korean Journal of Ophthalmology, 21(4), pp.189~194 (2007), 대한안과학회
- Xu KP, "Decrease in corneal sensitivity and change in tear function in dry eye", Cornea, 15, pp.235~239 (1996)
- Hiroko BM, "Cataract surgery in the presence of other ocular comorbidities" (2004), Saunders
- Walker TD, "Benzalkonium toxicity", Clin Experiment Ophthalmol, 32, pp.657~ (2004)
- 조양경, "Dry Eye After Cataract Surgeryand Associated Intraoperative Risk Factors", Korean Journal of Ophthalmology, 23(2), pp.65~73 (2009), 대한안과학회
- Donnenfeld ED, "Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation", J Cataract Refract Surg, 36, pp.1095~1100 (2010)